Presentation is loading. Please wait.

Presentation is loading. Please wait.

Blockade of CD11a by Efalizumab in Psoriasis Patients Induces a Unique State of T-Cell Hyporesponsiveness  Emma Guttman-Yassky, Yulia Vugmeyster, Michelle.

Published byJodie Bishop Modified over 5 years ago

Similar presentations

Presentation on theme: "Blockade of CD11a by Efalizumab in Psoriasis Patients Induces a Unique State of T-Cell Hyporesponsiveness  Emma Guttman-Yassky, Yulia Vugmeyster, Michelle."— Presentation transcript:

1 Blockade of CD11a by Efalizumab in Psoriasis Patients Induces a Unique State of T-Cell Hyporesponsiveness  Emma Guttman-Yassky, Yulia Vugmeyster, Michelle A. Lowes, Francesca Chamian, Toyoko Kikuchi, Mark Kagen, Patricia Gilleaudeau, Edmund Lee, Brisdell Hunte, Kathy Howell, Wolfgang Dummer, Sarah C. Bodary, James G. Krueger  Journal of Investigative Dermatology  Volume 128, Issue 5, Pages (May 2008) DOI: /jid Copyright © 2008 The Society for Investigative Dermatology, Inc Terms and Conditions

2 Figure 1 Inhibition of ex vivo anti-CD3-, anti-CD2, and anti-CD3/anti-CD28-induced activation of circulating T cells in efalizumab-treated psoriatic patients. (a) CD69 levels (MFI) on T cells stimulated ex vivo with increasing concentrations of anti-CD3 antibody at different time points during (up to day 84) and after efalizumab treatment. (b) CD11a expression on unstimulated T cells to assess CD11a saturation throughout the treatment period (up to day 84) and upon efalizumab washout. (c) A set of representative dot plots illustrates that efalizumab treatment by week 2 inhibits T-cell activation (CD69 MFI) induced by all three cell-surface stimuli, although less so with anti-CD3/CD28 stimuli. (d) Mean percent change in CD69 MFI with various stimuli, in patients on efalizumab treatment compared with baseline. *Indicates P<0.05. (e) Mean change in CD69 MFI with PMA/ionomycin stimulation on days 0 and 14 of efalizumab treatment showing no difference in T-cell activation by this stimuli. (f) A representative CD69 histogram for PMA/ionomycin stimulation illustrates that efalizumab treatment (black line, day 14) has no effect on PMA/ionomycin-mediated upregulation of CD69, as compared with baseline (gray line, day 0). Dotted line corresponds to the baseline CD69 expression on unstimulated T cells. Journal of Investigative Dermatology  , DOI: ( /jid ) Copyright © 2008 The Society for Investigative Dermatology, Inc Terms and Conditions

3 Figure 2 Inhibition of ex vivo anti-CD3- and anti-CD2-induced IFN-γ production by T cells in efalizumab-treated psoriatic patients. (a) T cells’ ability to synthesize IFN-γ in response to anti-CD3 antibody after 2 weeks of efalizumab treatment is highly diminished (P<0.02). (b) Representative FACS data for three different T-cell activation stimuli, anti-CD3, anti-CD2, PMA/ionomycin, at baseline and week 2 treatment with efalizumab. Efalizumab affected T-cell ability to produce IFN-γ in response to CD3 ligation but not to PMA/ionomycin stimulation. (c) Percent change in IFN-γ+ T cells in all study patients. Black lines correspond to individual patients. Journal of Investigative Dermatology  , DOI: ( /jid ) Copyright © 2008 The Society for Investigative Dermatology, Inc Terms and Conditions

4 Figure 3 Assessment of intracellular signalling through TCR/CD3 complex. Normal anti-CD3-mediated intracellular Ca2+ flux response in T cells from efalizumab-treated patient PBMCs that were loaded with Indo-1, activated with anti-CD3, and cross-linked with an anti-mouse IgG. The Ca+2 flux was measured as the ratio between bound and unbound Indo-1 versus time. (a) Intracellular Ca+2 flux from a representative normal volunteer pre- and post-stimulation with OKT3 (anti-CD3) and T11 (anti-CD2). (b and c) T cell intracellular Ca+2 flux responses from two representative patients are presented before and after efalizumab therapy. Journal of Investigative Dermatology  , DOI: ( /jid ) Copyright © 2008 The Society for Investigative Dermatology, Inc Terms and Conditions

5 Figure 4 Efalizumab-mediated inhibition of in vitro anti-CD3- and anti-CD3/anti-CD28-induced T-cell activation and the reversal of this inhibition by exogenous IL-2. (a) Anti-CD3-induced T-cell activation in the presence of the indicated concentration of efalizumab was measured by monitoring CD69 expression (geometric MFI) on CD2+ lymphocytes in whole blood obtained from normal healthy volunteers. A bar indicates efalizumab in vivo levels in psoriatic patients during therapeutic administration. (b) Anti-CD3-dependent PBMC proliferation in the presence of control IgG, efalizumab, monoclonal antibody MHM24 (murine parent of efalizumab), or Fab fragment of efalizumab was measured. (c) Anti-CD3/anti-CD28-dependent T-cell proliferation in the presence of efalizumab (1μgml−1) with and without IL-2 was assessed. Panels (b) and (c) show mean data (n=3), with error bars showing standard deviations. Journal of Investigative Dermatology  , DOI: ( /jid ) Copyright © 2008 The Society for Investigative Dermatology, Inc Terms and Conditions

6 Figure 5 Down-modulation of multiple cell-surface molecules in T cells from peripheral blood and lesional skin in efalizumab-treated psoriatic patients. (a) Mean level (MFI) of surface molecules on T cells at baseline and after 2 weeks of treatment for peripheral blood (study 1, open square; study 2, gray square) and lesional skin (black square). Asterisks (*) indicate that relative MFI values were statistically different compared with baseline, *P<0.05, **P<0.01, ***P< (b–g) A representative set of FACS dot plots from an individual patient (gated on T cells, except for panels (d) and (e)) is shown for peripheral blood (left) and lesional skin (right) at baseline and day 14. Quadrants were set on the basis of appropriate isotype controls. A fraction of positive cells in the indicated quadrants or an MFI value is shown. In panel (g), MFI values were calculated for T cells in the circled gate (CD29hi). Journal of Investigative Dermatology  , DOI: ( /jid ) Copyright © 2008 The Society for Investigative Dermatology, Inc Terms and Conditions

7 Figure 6 Down-modulation of VLA-4 and CD8 in peripheral blood CD8+ T cells in efalizumab-treated psoriatic patients. (a) Histograms for a representative patient illustrate bimodal distribution of VLA-4 (CD49d/CD29) at baseline (gray line) on CD8+ cells, and a subsequent shift in VLA-4hi/VLA-4lo ratio after 2 weeks of treatment. (b) Individual patient data were used to calculate the mean CD49d MFI for each time point and for each CD3+CD8+ subset, as indicated. Dotted line corresponds to baseline CD49d MFI value for the CD49dlo subset. (c) CD8 levels on all CD3+CD8+ cells were quantified throughout the treatment period (12 weeks) and upon efalizumab washout. Journal of Investigative Dermatology  , DOI: ( /jid ) Copyright © 2008 The Society for Investigative Dermatology, Inc Terms and Conditions

Download ppt "Blockade of CD11a by Efalizumab in Psoriasis Patients Induces a Unique State of T-Cell Hyporesponsiveness  Emma Guttman-Yassky, Yulia Vugmeyster, Michelle."

Similar presentations

Volume 132, Issue 3, Pages (March 2007)

Volume 132, Issue 3, Pages (March 2007)
Cheng-Ming Sun, Edith Deriaud, Claude Leclerc, Richard Lo-Man  Immunity 

Cheng-Ming Sun, Edith Deriaud, Claude Leclerc, Richard Lo-Man  Immunity 
Bart Tummers, Renske Goedemans, Veena Jha, Craig Meyers, Cornelis J. M

Bart Tummers, Renske Goedemans, Veena Jha, Craig Meyers, Cornelis J. M
Composition of Innate Lymphoid Cell Subsets in the Human Skin: Enrichment of NCR+ ILC3 in Lesional Skin and Blood of Psoriasis Patients  Marcel B.M. Teunissen,

Composition of Innate Lymphoid Cell Subsets in the Human Skin: Enrichment of NCR+ ILC3 in Lesional Skin and Blood of Psoriasis Patients  Marcel B.M. Teunissen,
Autoantibodies in Scurfy Mice and IPEX Patients Recognize Keratin 14

Autoantibodies in Scurfy Mice and IPEX Patients Recognize Keratin 14
CD271 on Melanoma Cell Is an IFN-γ-Inducible Immunosuppressive Factor that Mediates Downregulation of Melanoma Antigens  Junpei Furuta, Takashi Inozume,

CD271 on Melanoma Cell Is an IFN-γ-Inducible Immunosuppressive Factor that Mediates Downregulation of Melanoma Antigens  Junpei Furuta, Takashi Inozume,
Aurora Kinase A Is Upregulated in Cutaneous T-Cell Lymphoma and Represents a Potential Therapeutic Target  Daniel Humme, Ahmed Haider, Markus Möbs, Hiroshi.

Aurora Kinase A Is Upregulated in Cutaneous T-Cell Lymphoma and Represents a Potential Therapeutic Target  Daniel Humme, Ahmed Haider, Markus Möbs, Hiroshi.
Volume 136, Issue 4, Pages e3 (April 2009)

Volume 136, Issue 4, Pages e3 (April 2009)
Volume 141, Issue 1, Pages e2 (July 2011)

Volume 141, Issue 1, Pages e2 (July 2011)
Impaired Responses of Peripheral Blood Mononuclear Cells to Staphylococcal Superantigen in Patients with Severe Atopic Dermatitis: A Role of T Cell Apoptosis 

Impaired Responses of Peripheral Blood Mononuclear Cells to Staphylococcal Superantigen in Patients with Severe Atopic Dermatitis: A Role of T Cell Apoptosis 
Priti Agarwal, Mehdi Rashighi, Kingsley I. Essien, Jillian M

Priti Agarwal, Mehdi Rashighi, Kingsley I. Essien, Jillian M
C-CBL E3 Ubiquitin Ligase Is Overexpressed in Cutaneous T-Cell Lymphoma: Its Inhibition Promotes Activation-Induced Cell Death  Jianqiang Wu, Katrin A.

C-CBL E3 Ubiquitin Ligase Is Overexpressed in Cutaneous T-Cell Lymphoma: Its Inhibition Promotes Activation-Induced Cell Death  Jianqiang Wu, Katrin A.
CD300a is expressed on human B cells, modulates BCR-mediated signaling, and its expression is down-regulated in HIV infection by Rodolfo Silva, Susan Moir,

CD300a is expressed on human B cells, modulates BCR-mediated signaling, and its expression is down-regulated in HIV infection by Rodolfo Silva, Susan Moir,
Preactivation with IL-12, IL-15, and IL-18 Induces CD25 and a Functional High-Affinity IL-2 Receptor on Human Cytokine-Induced Memory-like Natural Killer.

Preactivation with IL-12, IL-15, and IL-18 Induces CD25 and a Functional High-Affinity IL-2 Receptor on Human Cytokine-Induced Memory-like Natural Killer.
Volume 138, Issue 5, Pages e2 (May 2010)

Volume 138, Issue 5, Pages e2 (May 2010)
Volume 132, Issue 7, Pages (June 2007)

Volume 132, Issue 7, Pages (June 2007)
HLA-A*0201+ Plasmacytoid Dendritic Cells Provide a Cell-Based Immunotherapy for Melanoma Patients  Caroline Aspord, Marie-Therese Leccia, Dimitri Salameire,

HLA-A*0201+ Plasmacytoid Dendritic Cells Provide a Cell-Based Immunotherapy for Melanoma Patients  Caroline Aspord, Marie-Therese Leccia, Dimitri Salameire,
Methods to Improve Adoptive T-Cell Therapy for Melanoma: IFN-γ Enhances Anticancer Responses of Cell Products for Infusion  Marco Donia, Morten Hansen,

Methods to Improve Adoptive T-Cell Therapy for Melanoma: IFN-γ Enhances Anticancer Responses of Cell Products for Infusion  Marco Donia, Morten Hansen,
Efalizumab Therapy for Atopic Dermatitis Causes Marked Increases in Circulating Effector Memory CD4+ T Cells That Express Cutaneous Lymphocyte Antigen 

Efalizumab Therapy for Atopic Dermatitis Causes Marked Increases in Circulating Effector Memory CD4+ T Cells That Express Cutaneous Lymphocyte Antigen 
The IL-17A-Producing CD8+ T-Cell Population in Psoriatic Lesional Skin Comprises Mucosa-Associated Invariant T Cells and Conventional T Cells  Marcel.

The IL-17A-Producing CD8+ T-Cell Population in Psoriatic Lesional Skin Comprises Mucosa-Associated Invariant T Cells and Conventional T Cells  Marcel.

Similar presentations

Ads by Google